

Informazione Regolamentata n. 0696-50-2015	Data/Ora Ricezione 30 Aprile 2015 22:16:02	MTA
--	---	-----

Societa' : CTI BIOPHARMA  
Identificativo : 57538  
Informazione  
Regolamentata  
Nome utilizzatore : CELLN01 - Villa  
Tipologia : AVVI 01  
Data/Ora Ricezione : 30 Aprile 2015 22:16:02  
Data/Ora Inizio : 30 Aprile 2015 22:31:03  
Diffusione presunta  
Oggetto : CTI BioPharma Announces Filing of Form  
10-K/A

*Testo del comunicato*

Vedi allegato.



## **CTI BioPharma Announces Filing of Form 10-K/A**

SEATTLE, Wash., April 30, 2015—CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today announced that it has filed a Form 10-K/A to amend its Annual Report on Form 10-K for the year ended December 31, 2014 that was originally filed on March 12, 2015.

The Form 10-K/A was filed solely to include the information required in Part III, Items 10, 11, 12, 13 and 14 of Form 10-K that was previously omitted from the original Form 10-K in reliance upon U.S. Securities and Exchange Commission rules that allow such omitted information to be filed as an amendment to the original Form 10-K or incorporated by reference from the registrant's definitive proxy statement that involves the election of directors not later than 120 days after the end of the fiscal year covered by the original Form 10-K. We filed this Form 10-K/A to include the information required by Part III, Items 10, 11, 12, 13 and 14 of the original Form 10-K because we no longer intend to file such definitive proxy statement within 120 days after the end of our fiscal year covered by the original Form 10-K.

This filing is available for review on CTI BioPharma's website at [www.ctibiopharma.com](http://www.ctibiopharma.com), on the U.S. Securities and Exchange Commission's website at [www.sec.gov](http://www.sec.gov), and on the authorized storage system "NIS Storage" website [www.emarketstorage.com](http://www.emarketstorage.com).

### **About CTI BioPharma**

CTI BioPharma Corp. (NASDAQ and MTA: CTIC) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma's lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited. For additional information and to sign up for email alerts and get RSS feeds, please visit [www.ctibiopharma.com](http://www.ctibiopharma.com).

Source: CTI BioPharma Corp.

###

#### **Contacts:**

Monique Greer  
+1 206-272-4343  
[mgreer@ctibiopharma.com](mailto:mgreer@ctibiopharma.com)

Ed Bell  
+1 206-282-7100  
[ebell@ctibiopharma.com](mailto:ebell@ctibiopharma.com)

In Europe:  
CTI Life Sciences Limited, Milan Branch

Laura Villa  
+39 02 94751572  
[lvilla@cti-lifesciences.com](mailto:lvilla@cti-lifesciences.com)

Fine Comunicato n.0696-50

Numero di Pagine: 3